Pomerantz LLP is investigating claims on behalf of investors of Alibaba Group Holding Limited. The investigation concerns whether Alibaba and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On June 24, 2026, the Financial Times reported that Anthropic accused Alibaba of obtaining illicit access to its AI model Claude by creating fake accounts, after which Alibaba’s American Depositary Receipt price fell $7.53 per ADR, or 7.34%, over two trading sessions to close at $95.07 per ADR on June 25, 2026. Then on July 1, 2026, the U.S. Department of Justice announced Alibaba entered a non-prosecution agreement to pay $600 million to resolve allegations of violating the Federal Food, Drug, and Cosmetic Act by failing to prevent merchants from selling illegal pharmaceuticals and related items into the United States, and Alibaba’s ADR price fell $1.85 per ADR, or 1.9%, to close at $96.14 per ADR on July 2, 2026.
Alibaba Group Holding LtdDOJ non-prosecution agreement for $600M over illegal pharmaceutical sales, and securities fraud investigation
Astera Labs, Inc.